Fusion Antibodies (LON:FAB) Issues Quarterly Earnings Results

Fusion Antibodies (LON:FAB) released its earnings results on Monday. The company reported GBX (1.20) earnings per share for the quarter, Digital Look Earnings reports. Fusion Antibodies had a negative return on equity of 210.32% and a negative net margin of 91.92%.

Fusion Antibodies Trading Down 20.3%

Shares of FAB traded down GBX 2.30 during mid-day trading on Monday, reaching GBX 9.05. The company had a trading volume of 2,113,557 shares, compared to its average volume of 416,821. The stock has a market cap of £11.33 million, a price-to-earnings ratio of -6.03 and a beta of 1.24. The firm has a fifty day simple moving average of GBX 10.89 and a 200-day simple moving average of GBX 12.20. Fusion Antibodies has a fifty-two week low of GBX 9 and a fifty-two week high of GBX 21. The company has a current ratio of 1.80, a quick ratio of 2.36 and a debt-to-equity ratio of 92.42.

Fusion Antibodies Company Profile

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.